Sign in
NRSN Stock Price, Chart, Stats & News
NeuroSense Therapeutics Ltd.
Save
NeuroSense Therapeutics Ltd. (NRSN) does not currently pay a dividend.
7.12M
Market cap
–
Current P/E
–
Forward P/E
NRSN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -514.13% |
ROE | 2720.50% |
D/E | – |
Interest coverage ratio | -97.39x |
NRSN valuation
P/E | – |
P/S | – |
P/B | -35.78x |
P/CF | -9284.43x |
P/FCF | -9015.67x |
P/OCF | -9284.43x |
PEG | 0.14x |
EV multiple | -2.19x |
About
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease.
Similar securities
Based on sector and market capitalization
Report issue